GeneDx Holdings’ Q2 2026 Call: Sales Force Reliance, ASP Parity Timelines Clash

Date of Call: Aug 3, 2026

Financials Results

• Revenue: $114.4M, up 11% YOY
• Gross Margin: 70%

Guidance:

• Reaffirmed full-year 2026 revenue guidance range of $475M to $490M.
• Expect exome and genome volume growth of at least 30% for full year 2026.
• Expect exome and genome revenue growth of at least 20% for full year 2026.
• Q3 2026 revenue expected between $122M and $124M.
• Q3 gross margin expected to be approximately 70%.
• Q3 exome and genome revenue expected between $110M and $112M.
• Q3 volume expected to be approximately 33,200 tests.
• Q3 adjusted net income expected to be approximately $2M.

Business Commentary:

Revenue and Volume Growth:

• GNDX reported $114.4 million in total revenue for Q2 2026, up 11% year-over-year, with exome and genome revenues at $100.3 million, up 785% year-over-year.
• The growth was driven by a 32% increase in exome and genome test volumes, reaching 30,700 tests, with strong demand across geneticists, pediatric neurology, and prenatal sectors.

Optimizing Unit Economics:

• GNDX's blended average reimbursement rate in Q2 was $3,200, with a focus on optimizing product mix, expanding payer coverage, and improving revenue cycle management.
• The company aims to improve collection rates for genome tests, which currently stand at approximately 32%, by enhancing payer-specific workflows and leveraging increased coverage.

Market Expansion and Coverage:

• Commercial coverage for genome tests expanded significantly, with 87% of commercial lives now having some level of coverage, up from 47% last quarter.
• This was driven by efforts in advocacy and evidence generation, which helped demonstrate the medical necessity of genomic testing.

Operational and Financial Improvements:

• GNDX achieved profitability with adjusted net income of $0.4 million, an improvement from a loss in Q1, and expects to sustain positive cash flow by 2027.
• Cost management initiatives, including a $25 million reduction in operating expenses, and investments in technology and sales force expansion contributed to these improvements.

Competitive Positioning and Market Share:

• GNDX maintained an 80% market share among geneticists and expanded to pediatric neurologists, with a 50% market share in that segment.
• The company's competitive edge is attributed to its deep clinical data, high diagnostic yield, and strong customer support, which are critical in the rare disease testing market.

Sentiment Analysis:

Overall Tone: Positive

• Management stated: "Demand for our services has never been higher." "We are confident we can drive collections to the industry-standardized this massive revenue opportunity ahead." "We expect meaningful improvements in Q4 2026, with the most significant uplift coming in 2027." "Our core market ability to drive ARR improvements up this Q2 baseline."

Q&A:

• Question from Dan Brennan (TD Cowen): Can you elaborate on the pacing of improvements in collection rates for Q3 and Q4? Why is the pace slower in Q3 and what's the upside case?
  Response: Collection rates expected to remain roughly flat in Q3; meaningful improvements and the upside are expected to begin in Q4 2026, with the most significant uplift in 2027 as coverage expands and operational execution improves.

• Question from Dan Brennan (TD Cowen): How are you managing the mix between exome and genome, and could competitor push for whole genome be a disadvantage?
  Response: The company sees the future as genome but uses exome as a bridge (80% of patients can be diagnosed with exome). They are successfully managing the transition and ensuring customer choice, with exome collection rates comparable to genome, indicating room for improvement across the portfolio.

• Question from Mark Massaro (BTIG): Can you double-click on the Paralon opportunity and frame what needs to happen next? Why wouldn't this be a lift in Q3/Q4?
  Response: Carillon expanded coverage to 87% of commercial lives, but payers take time to operationalize policies. Contribution is expected to begin in Q4 2026, with a more full impact in 2027.

• Question from Mark Massaro (BTIG): When do you expect a benefit from Medi-Cal coverage in California, and could there be anything in Q3?
  Response: Medi-Cal coverage effective July 1st; monitoring adjudication. Some contribution expected, but a greater uplift is anticipated in 2027 as managed care organizations follow policy.

• Question from Mark Massaro (BTIG): Can you quantify early orders from general pediatricians and discuss lessons learned?
  Response: Still early stages; seeing interest and some first orders. Strategy focuses on higher productivity physicians and targeting corporate accounts to aggregate demand and set policy.

• Question from William Bonello (Craig-Hallum): Why did mix improvement not lead to higher ARR, and is pricing pressure involved?
  Response: Mix improvement (lower genome mix) led to a slight drop in ARR, but the company is focused on improving operational effectiveness, particularly collection rates, which are the largest opportunity to increase earnings power.

• Question from William Bonello (Craig-Hallum): How do you reconcile flat volume/revenue guidance with expectations for steady ARR improvement?
  Response: The guidance reflects positive trends seen in July, including mix moving in the right direction and reflex volumes exceeding genomes, incorporated into the new outlook.

• Question from David Westenberg (Piper Sandler): How much visibility do you have on collection rates for Q4, and what about sales force productivity?
  Response: Visibility is based on data trends through July and internal improvements in revenue cycle management. Sales force productivity is positive, with investments in hiring and processes driving adoption.

• Question from David Westenberg (Piper Sandler): How are you thinking about cash flow and becoming sustainably cash positive?
  Response: Q2 will be the high point of the year for cash flow. Factors converging for strong, sustained cash generation by 2027 include completed cost actions, RCM improvements raising earnings, volume growth, operating margin expansion, and the Blackstone financing providing runway.

• Question from Kyle Mixon (Canaccord Genuity): How does higher reflex mix impact guidance, especially ARR?
  Response: Reflex volumes are expected to be reimbursed at exome rates; genome mix is expected to be at or slightly lower than current levels in the back half, incorporated into the guide.

• Question from Kyle Mixon (Canaccord Genuity): Which end markets saw the most volume increase?
  Response: Reflex product is a bridge, primarily in geneticist channel. Exome utilization is strong in pediatric neurology, and NICU continues to be a key driver.

• Question from Tycho Peterson (Jefferies): How do you characterize the competitive landscape now?
  Response: GDX remains the dominant player with 80% market share among geneticists. The company's unique Infinity database provides higher diagnostic yield, driving discovery and leadership in the market.

• Question from Tycho Peterson (Jefferies): Where are you in rolling out the one-minute genome and how critical is it?
  Response: Progress is good; one-minute ordering is on track for a rolling release later this summer, designed by general pediatricians to unlock volume across all channels.

• Question from Guggenheim: What are your assumptions for exome/genome mix exiting the year?
  Response: Genome mix expected to be around 30%, maybe slightly lower in the second half, based on recent order flows.

• Question from Guggenheim: What's different about the new approach to revenue cycle management?
  Response: Historically under-invested in payer-specific processes; now bringing in experienced personnel with a playbook to comply precisely with payer requirements to improve collection rates.

• Question from Guggenheim: How is productivity going with the new sales reps?
  Response: Positive return on investment so far; productivity is expected to accelerate, complemented by tools like one-minute ordering and market-specific customer service.

• Question from Keith Hinton (Freedom Capital Markets): What is the contribution from various expansion markets, and what about gross margin?
  Response: Growth is broad-based, with core markets (geneticists, pediatric neurology, NICU) contributing the most due to larger bases; newer markets (general pediatrics) show promise. Significant headroom remains in core markets.

• Question from Keith Hinton (Freedom Capital Markets): What drove the 200 bps gross margin improvement quarter over quarter, and is it sustainable?
  Response: Improvements driven by reductions in input costs, wet lab efficiency gains, and significant dry lab productivity gains, especially from deploying AI/ML tools. The company expects to realize even greater efficiencies over time.

Contradiction Point 1

Sales Force Productivity and Guidance Reliance

Contradiction on the maturity and contribution of new sales teams to volume guidance.

William Bonello (Craig-Hallum) - William Bonello (Craig-Hallum)

2026Q2: The guidance incorporates positive July trends... The company sees healthy demand and is confident in the guide despite the focus on improving unit economics. - [Kevin Feely](CFO)

How do you reconcile flat volume and revenue guidance with steady ARR growth expectations? - David Westenberg (Piper Sandler & Co.)

2026Q1: The updated guidance is built from the core business with 'tighter assumptions' and less reliance on areas with limited visibility, such as new sales reps in new channels. - [Kevin Feeley](CFO)

Contradiction Point 2

Genome/Exome Mix and ASP Outlook

Contradiction on the timeline and mechanism for achieving genome ASP parity with exome.

David Westenberg (Piper Sandler) - David Westenberg (Piper Sandler)

2026Q2: The company is focused on... improving revenue cycle management to drive improvements. Strong sustained cash generation is expected by 2027. - [Catherine Stoolin](COO) / [Kevin Feely](CFO)

How are you thinking about cash flow, and when will GDX become sustainably cash positive? - David Westenberg (Piper Sandler & Co.)

2026Q1: Genome ASP can reach parity with exome through improving commercial coverage and reducing denials via better revenue cycle processes... This will take 'a number of quarters.' - [Kevin Feeley](CFO)

Contradiction Point 3

Outlook for General Pediatrics Market Contribution

Timing for material revenue inflection from new pediatric market.

Mark Massaro (BTIG) - Mark Massaro (BTIG)

2026Q2: The general pediatrics channel is still early-stage, but there is good interest and some first orders. - [Catherine Stoolin](CEO)

What are the early order numbers from the general pediatrics market and what lessons have been learned? - David Westenberg (Piper Sandler)

2025Q4: Volumes are expected to pick up in Q4 2026 and accelerate into 2027. - [Katherine Stueland](CEO)

Contradiction Point 4

Expectations for Medi-Cal/Medicaid Coverage Impact

Inclusion of new Medicaid coverage in financial guidance.

Mark Massaro (BTIG) - Mark Massaro (BTIG)

2026Q2: Medi-Cal fee-for-service coverage went live July 1st... Trends suggest potential for a greater uplift in 2027. - [Kevin Feely](CFO)

When do you expect a benefit from Medi-Cal (California Medicaid) coverage, and could there be an impact in Q3? - Daniel Brennan (TD Cowen)

2025Q4: The guide assumes flat pricing for exome/genome, with no Medi-Cal or new Medicaid state coverage baked in due to uncertainty. - [Kevin Feeley](CFO)

Contradiction Point 5

Guidance for Sales Force Productivity and Operating Margin

Expectation for operating result in Q1.

William Bonello (Craig-Hallum) - William Bonello (Craig-Hallum)

2026Q2: The guidance incorporates positive July trends... The company sees healthy demand and is confident in the guide despite the focus on improving unit economics. - [Kevin Feely](CFO)

How do you reconcile flat volume and revenue guidance with steady ARR growth? - Brandon Couillard (Wells Fargo)

2025Q4: Q1 is expected to be close to breakeven, not a loss, with operating margin building through the year as the new sales reps become productive. - [Kevin Feely](CFO)